Dr. Reddy’s confirmed that it recalled all of its over-the-counter and prescription ranitidine products on Oct. 1 due to detection of N-nitrosodimethylamine (NDMA).

The company said the recall applied to all products with expiration dates between Sept. 2019 and June 2021. The action followed the FDA’s alert to patients and healthcare professionals that NDMA was found in ranitidine samples.

The company said that it had received no reports of adverse events related to ranitidine. Dr. Reddy’s suspended global sales of ranitidine pending the FDA’s investigation of the possible carcinogen in the heartburn drug.